Skip to main content
72°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
RLFTY
)
1.470
UNCHANGED
Streaming Delayed Price
Updated: 2:57 PM EDT, Aug 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about RLFTY
< Previous
1
2
3
4
Next >
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19
May 26, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / May 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF), (OTCQB:RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Relief Therapeutics Expands U.S. Commercial Team
May 23, 2022
Tracy Truong and Kelli Powell Appointed Regional Clinical Specialists for the West and Northeast Regions, RespectivelySeasoned Account Managers Bring Extensive Pharmaceutical Sales Experience in Rare...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
May 11, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / May 11, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (" Relief "), announced today that it has filed Amendment No. 2 to its Registration...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
Relief Therapeutics to Participate in Industry and Investor Conferences in May
May 09, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / May 9, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
May 06, 2022
NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY)...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
Product Safety
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
May 06, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTY) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)
April 27, 2022
Notice of Allowance of Patent Application for Modified Release Orally Administered Amino Acid Formulations, Strengthens Proprietary Position in U.S. until 2036 GENEVA, SWITZERLAND / ACCESSWIRE / April...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing
April 26, 2022
Proven Pharmaceutical Marketing Leader Brings Extensive Experience in Rare Diseases, Digital Innovation and New Product Launches to Relief's U.S. Commercial Team GENEVA, SWITZERLAND / ACCESSWIRE /...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil
April 22, 2022
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil in a Subgroup of Patients with Critical COVID-19 with Respiratory Failure that...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
April 12, 2022
NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / April 12, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process
April 05, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / April 5, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), today reported that it has entered into a stipulation to stay the...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
April 01, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / April 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
April 01, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / April 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Reports Full-Year 2021 Results and Provides Corporate Update
March 31, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / March 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
March 28, 2022
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports In Vivo Data Published in the Peer Reviewed, International Journal of Molecular Sciences, Indicating Prolonged Release...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
March 24, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / March 24, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic relief...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
March 21, 2022
Proven Pharmaceutical Sales Professional Brings Big Pharma Experience to Relief's U.S. Expansion Activities GENEVA, SWITZERLAND / ACCESSWIRE / March 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF,...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
March 21, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / March 21, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY)("Relief"), announced today that it has filed Amendment No. 1 to its Registration...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
March 17, 2022
Despite Primary Endpoint not Being Met, Due to Small Sample Size, Results Show a Very Positive Trend in Efficacy Parameters with a Clean Safety and Tolerability Profile GENEVA, SWITZERLAND / ACCESSWIRE...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
March 15, 2022
Company Signs Binding Term Sheet to Acquire Worldwide Commercialization Rights, Except in the United Kingdom Expands on Existing PKU GOLIKE(R) Portfolio of Products GENEVA, SWITZERLAND / ACCESSWIRE /...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
February 16, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / February 16, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
February 08, 2022
No Notice of Opposition or Extension Request has Been Received in Relation to the Application; Certificate of Registration Expected by Late April GENEVA, SWITZERLAND / ACCESSWIRE /February 8, 2022 /...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
February 02, 2022
Industry Executive Brings Nearly 30 Years of Biopharmaceutical Sales and Commercial Expertise GENEVA, SWITZERLAND / ACCESSWIRE / February 2, 2022 / RELIEF THERAPEUTICS Holding SA...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease
February 01, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / February 1, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Therapeutics Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
January 31, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 31, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge
January 27, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 27, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Death
Exposures
COVID-19
Death
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering Ready to Use Diclofenac Stick Packs
January 24, 2022
Notice of Allowance of Patent Application for a Non-Steroidal Anti-Inflammatory, Diclofenac Potassium, Strengthens Proprietary Position in U.S. until 2039 GENEVA, SWITZERLAND / ACCESSWIRE / January 24,...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Relief Reports US Collaboration Partner Announces Expansion of Aviptadil US Expanded Access & Right to Try Programs for Patients w/COVID-19 Respiratory Failure who've Exhausted All Approved Therapies
January 19, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 19, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Exposures
COVID-19
Relief Therapeutics Comments on NRx Pharmaceuticals' Press Release Reporting on its Recently Filed Lawsuit
January 14, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients therapeutic...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
Relief Comments on Lawsuit Filed Against It by NeuroRx
January 12, 2022
GENEVA, SWITZERLAND / ACCESSWIRE / January 12, 2022 / RELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (" Relief "), a biopharmaceutical company seeking to provide patients...
From
Relief Therapeutics Holdings AG
Via
AccessWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.